

# Dasabuvir

## Catalog No: tcsc2028



### Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



### Specifications

**CAS No:**  
1132935-63-7

**Formula:**  
 $C_{26}H_{27}N_3O_5S$

**Pathway:**  
Anti-infection

**Target:**  
HCV

**Purity / Grade:**  
>98%

**Solubility:**  
DMSO :  $\geq 46$  mg/mL (93.20 mM)

**Alternative Names:**  
ABT-333


**Observed Molecular Weight:**  
493.57

## Product Description

Dasabuvir (ABT-333) is a nonnucleoside inhibitor of the RNA-dependent RNA polymerase encoded by the **HCV NS5B** gene, inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates, with **IC<sub>50</sub>** between 2.2 and 10.7 nM.

IC50 & Target: IC50: 2.2-10.7 nM (NS5B polymerase)<sup>[1]</sup>

**In Vitro:** Dasabuvir (ABT-333) is at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases. Dasabuvir (ABT-333) inhibits the polymerase enzymatic activity of genotype 1 laboratory strain enzymes (H77, BK, N, and Con1 strains), as well as enzymes produced from polymerase genes from HCV genotype 1-infected subjects, with IC<sub>50</sub>s between 2.2 and 10.7 nM. Dasabuvir (ABT-333) inhibits replication of HCV subgenomic replicons in cell culture assays, with EC<sub>50</sub> values of 7.7 and 1.8 nM against genotype 1a (H77) and 1b (Con1), respectively. In the presence of 40% human plasma, there is a 12- to 13-fold decrease in inhibitory potency, yielding EC<sub>50</sub>s of 99 and 21 nM for HCV genotype 1a (H77) and 1b (Con1) replicons, respectively<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!